KalVista Pharmaceuticals (KALV) Debt to Equity (2016)
Historic Debt to Equity for KalVista Pharmaceuticals (KALV) over the last 3 years, with Q1 2016 value amounting to $0.11.
- KalVista Pharmaceuticals' Debt to Equity rose 21805.97% to $0.11 in Q1 2016 from the same period last year, while for Mar 2016 it was $0.11, marking a year-over-year increase of 21805.97%. This contributed to the annual value of -$0.0 for FY2016, which is N/A changed from last year.
- Latest data reveals that KalVista Pharmaceuticals reported Debt to Equity of $0.11 as of Q1 2016, which was up 21805.97% from $0.09 recorded in Q4 2015.
- KalVista Pharmaceuticals' 5-year Debt to Equity high stood at $0.11 for Q1 2016, and its period low was -$0.1 during Q4 2014.
- Moreover, its 3-year median value for Debt to Equity was $0.08 (2015), whereas its average is $0.03.
- In the last 5 years, KalVista Pharmaceuticals' Debt to Equity soared by 19311.37% in 2015 and then skyrocketed by 21805.97% in 2016.
- Over the past 3 years, KalVista Pharmaceuticals' Debt to Equity (Quarter) stood at -$0.1 in 2014, then soared by 193.11% to $0.09 in 2015, then rose by 15.53% to $0.11 in 2016.
- Its Debt to Equity stands at $0.11 for Q1 2016, versus $0.09 for Q4 2015 and $0.08 for Q3 2015.